FDA Drug recall D-0101-2023
Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 3053…
- FDA Drug
- Class II
- terminated
- Published 2023-01-18
On 2023-01-18 the FDA classified a Class II recall of Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 3053… by Direct Rx, citing cGMP deviation: discontinue of stability support for product.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0101-2023 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2022-11-02 |
| Published | 2023-01-18 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Direct Rx |
| Distribution | FL |
Product
Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 30534, NDC 72189-0334-05
Reason
cGMP deviation: discontinue of stability support for product.
Identifiers
| code_info | Lot #: 07MA2232, Exp. 4/30/23 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0101-2023%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.